Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azacitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacitidine SCHEMBL17537438 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL169369 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL706302 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL16187746 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL18055593 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL7146234 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL23815524 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL13376157 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL2412035 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Fazarabine SCHEMBL3278 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | FORTY SEVEN, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220401516-A1 | COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCER | ALX Oncology Inc. | 2022-12-22 | — | — | US | disclosed |
| EP-3692983-B1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210115140-A1 | COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA | Forty Seven, LLC | 2021-04-22 | — | — | US | disclosed |
| US-20200360372-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | ASTELLAS PHARMA INC. (JP) | 2020-11-19 | — | — | US | disclosed |
| US-20200231694-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOGUE | BERLIN-CHEMIE AG (DE) | 2020-07-23 | — | — | US | disclosed |
| EP-2909214-B1 | ETP DERIVATIVES | HOPE CITY (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200163978-A1 | IBANDRONATE CONJUGATES OF NUCLEOSIDE ANTIMETABOLITES | MBC PHARMA, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190201431-A1 | EX VIVO METHODS OF INDUCING IDO EXPRESSION IN ANTIGEN PRESENTING CELLS USING A COMPOUND SELECTED FROM THE GROUP CONSISTING OF AZACYTIDINE, AND DECITABINE | IDOGEN AB (SE) | 2019-07-04 | — | — | US | disclosed |
| US-9951098-B2 | Synthesis of 5-azacytidine | PHARMION LLC (US) | 2018-04-24 | — | — | US | disclosed |
| WO-2018053345-A1 | DITHIO ETP DERIVATIVES | CITY OF HOPE (US) | 2018-03-22 | — | — | WO | disclosed |
| EP-2691408-B1 | SYNTHESIS OF 5-AZACYTIDINE | CELGENE INT SÁRL (CH) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163978-A1 | IBANDRONATE CONJUGATES OF NUCLEOSIDE ANTIMETABOLITES | BPGM, SLC29A1, ENTPD5 | DNMT1 1722/4885LMNA 2664/4885MTOR 2647/4885 |
| US-20200231694-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOGUE | BST2, CD38, ENTPD5 | DNMT1 1250/4885LMNA 3040/4885MTOR 3858/4885 |
| US-11795223-B2 | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia | CD47, MCL1, MYADM | DNMT1 13/4885LMNA 1824/4885MTOR 1710/4885 |
| US-20220401516-A1 | COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCER | DNMT1, DNMT3A, MECP2 | DNMT1 1/4885LMNA 2700/4885MTOR 2666/4885 |
| US-20200360372-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, MYD88 | DNMT1 428/4885LMNA 3508/4885MTOR 2543/4885 |
| US-20190201431-A1 | EX VIVO METHODS OF INDUCING IDO EXPRESSION IN ANTIGEN PRESENTING CELLS USING A COMPOUND SELECTED FROM THE GROUP CONSISTING OF AZACYTIDINE, AND DECITABINE | IDO1, IDO2, INMT | DNMT1 54/4885LMNA 4342/4885MTOR 2381/4885 |
| US-20210115140-A1 | COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA | CD47, MCL1, MYADM | DNMT1 13/4885LMNA 1824/4885MTOR 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.